Most recently Omead Ostadan exercised 3,540 shares worth $131,121.60 on 1 December 2017.
|Shares||Price per share||Total price||Shares after||Source|
|2017-12-01||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Option exercise||3,540||$37.04||$131,121.60||26,827||SEC insider form 4|
|2017-08-07||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||1,671||$195.26||$326,279.46||24,571||SEC insider form 4|
|2017-07-07||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||1,672||$172.73||$288,804.56||26,242||SEC insider form 4|
|2017-05-08||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||1,672||$186.10||$311,159.20||27,914||SEC insider form 4|
|2017-03-24||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||1,672||$170.00||$284,240.00||29,586||SEC insider form 4|
|2017-02-15||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Option exercise||8,438||$0.00||$0.00||33,009||SEC insider form 4|
|2017-02-13||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||2,173||$163.10||$354,416.30||24,571||SEC insider form 4|
|2017-02-02||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||1,104||$160.41||$177,092.64||26,586||SEC insider form 4|
|2017-01-30||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||259||$160.90||$41,673.10||27,690||SEC insider form 4|
|2017-01-17||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||2,378||$160.06||$380,622.68||28,662||SEC insider form 4|
|2016-12-15||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||2,000||$126.16||$252,320.00||31,040||SEC insider form 4|
|2016-12-08||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||3,000||$121.63||$364,890.00||52,988||SEC insider form 4|
|2016-12-01||ILMN||Omead Ostadan||EVP Ops, Products, Strategy||Sale||3,000||$133.30||$399,900.00||51,492||SEC insider form 4|
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina's BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.